Navigation Links
PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
Date:8/6/2008

1,169 1,169 1,436

Restructuring benefit - - 40

Total costs and expenses 304,992 304,992 237,079

Income from operations 26,935 26,935 16,903

Other income (expense) (726) (726) 370

Income before income taxes 26,209 26,209 17,273

Provision for income taxes 877 8,706 (b) 9,583 6,908

Effective tax rate 3.3% 36.6% 40.0%

Minority interest expense

(benefit) 294 294 (70)

Net income $25,038 $(8,706) $16,332 $10,435

Earnings per common share:

Basic $0.44 $0.29 $0.19

Diluted $0.43 $0.28 $0.18

Shares used in computing

earnings per common share:

Basic 56,602 56,602 55,081

Diluted 57,711 57,711 56,851

Balance Sheet Information Preliminary

June 30, March 31, June 30,

2008 2008 2007

Billed accounts receivable, net $253,256 $216,060 $189,843

Unbilled accounts receivable, net 222,560 197,627 135,178

Deferred revenue (213,126) (199,121) (170,718)

Net receivables $262,690 $214,566 $154,303

Cash and marketable securities $51,918 $53,313 $96,677

Working capital $172,315 $165,437 $118,746

Total assets $941,757 $859,638 $680,013

Short-term borrowi
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer
2. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2008 Earnings Release and Conference Call
3. PAREXEL International Updates Earnings Guidance in Conjunction with Its Investor Day
4. PAREXEL Expands Global Clinical Logistics Capabilities
5. Parexel Invites Public to Listen to Live Webcast of Its Investor Day June 25, 2008
6. PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies
7. PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting
8. PAREXEL Reaches Agreement To Acquire ClinPhone
9. PAREXEL International to Present at Goldman Sachs 29th Annual Global Healthcare Conference
10. PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention
11. PAREXEL Appoints Leading Biostatistician Dr. Imogene Grimes to Vice President of Data Sciences Strategic Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Austin, TX (PRWEB) September 18, 2014 ... of integrated urological and interventional radiology products and ... (also known as cryotherapy and cryoablation) versus external ... Mid-Atlantic Section of the American Urological Association (MAAUA) ... , "Comparing Relative Effectiveness of Cryosurgery and ...
(Date:9/18/2014)... September 18, 2014 ... http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the addition ... Global Strategic Business Report" report ... ,This report analyzes the worldwide markets ... by the following Product Segments: Polymeric ...
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... "Global Human Albumin Industry Report 2014" report to ... Industry Report 2014 is a professional and in-depth study ... industry. The report provides a basic overview ... chain structure. The human albumin market analysis is provided ...
(Date:9/18/2014)... LEXINGTON, Ky. , Sept. 18, 2014  Neogen ... it has entered into a strategic agreement with Merck ... Heifer Program. The Igenity Dairy Heifer ... producers essential information on the genetic potential of replacement ... after a calf is born, and is an excellent ...
Breaking Biology Technology:HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Merck Animal Health to market Neogen's dairy genomic program 2
... 11 STAAR Surgical Company (Nasdaq: STAA ... invasive ophthalmic products, today announced that the FDA has ... use with the Affinity(TM) Collamer(R) Three-Piece NTIOL and the ... usher in a new era of insertion devices for ...
... June 11 Repligen Corporation (Nasdaq: RGEN ) ... 2009, ended March 31, 2009. Total revenue for fiscal ... for fiscal year 2008 ended March 31, 2008, an increase ... was comprised of Protein A product revenue, and royalty and ...
... , - Phase 2 continuation data demonstrated sustained improvement in disease ... - , , - Frequency of disease flares as ... or B organ domain scores decreased over four years of BENLYSTA ... events, serious adverse events, malignancies or serious infections over time - ...
Cached Biology Technology:STAAR Surgical Receives FDA Clearance for the Epiphany(TM) Injector System 2STAAR Surgical Receives FDA Clearance for the Epiphany(TM) Injector System 3Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results 2Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results 3Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results 4Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results 5Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results 6Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results 7Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus 7Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus 8
(Date:9/18/2014)... disciplines will be celebrated tonight at the third annual ... the health of premature infants and in paving the ... whose work was supported by the National Science Foundation, ... Energy Commission, will be honored at a ceremony at ... group of Members of Congress will be on hand ...
(Date:9/18/2014)... the fish world, are the ideal animal in which ... moved from the ocean into tens of thousands of ... changing their skeleton to adapt to the new environment. ... sticklebacks now have turned up one of the genes ... change in that gene,s regulation in a freshwater population ...
(Date:9/17/2014)... were instrumental in the creation of the Santa Ana ... the fire threat potential of the powerful, hot, dry ... an inferno. The index was introduced Sept. 17 by ... San Diego Gas and Electric. , The index includes ... will be used to help fire agencies and other ...
Breaking Biology News(10 mins):3rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2
... the University of Pennsylvania have found that deleting a gene ... of stem cell reservoirs in adult mice. This gene, ATR, ... mutations in proteins in the DNA damage response underlie certain ... appears in the inaugural issue of Cell Stem Cell. ...
... Spring Harbor, N.Y. – Cold Spring Harbor Laboratory (CSHL) ... and Howard Hughes Medical Investigator (HHMI) Greg Hannon have ... a critical tumor suppressor network, called the p53 pathway, ... moving simultaneously on several fronts to understand the p53 ...
... the length of nectar spurs--the long tubes leading to ... match the tongue lengths of the pollinators that drink ... Justen Whittall of the University of California at Davis ... Santa Barbara. They were funded by the National Science ...
Cached Biology News:Loss of stem cells correlates with premature aging in animal study 2Study shows big power of small RNAs, not just proteins, in halting cancer 2Columbine flowers develop long nectar spurs in response to pollinators 2
SphingoStripsTM contain fifteen different biologically active, nitrocellulose-immobilized lipids at 100 pmol per spot, which can be assayed for protein binding and specificity using a simple blot ove...
Mouse monoclonal antibody raised against a partial recombinant KRT4. NCBI Entrez Gene ID = KRT4...
... ,High Quality, Functionally-Validated, Ion Channel Cell Lines ... having a critical role in nerve and ... function in pain, CNS and the heart. ... investigated in therapeutic areas, such as neuropathic ...
... Ion Channel Cell Lines ,High Quality, Functionally-Validated, ... are well known for having a critical ... consequently have a key function in pain, ... ion channels have been investigated in therapeutic ...
Biology Products: